上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2014年
11期
15-18
,共4页
原发性免疫性血小板减少症%血小板减少症%治疗
原髮性免疫性血小闆減少癥%血小闆減少癥%治療
원발성면역성혈소판감소증%혈소판감소증%치료
primary immune thrombocytopenia%thrombocytopenia%treatment
原发性免疫性血小板减少症是一种免疫介导的获得性血小板减少所致出血性疾病，其患者外周血小板计数＜100×109/L，但没有引起血小板减少的明显诱因或基础疾病。近年来，随着对此疾病发病机制的认识逐渐深入，在其治疗方面也有了很多新的进展。
原髮性免疫性血小闆減少癥是一種免疫介導的穫得性血小闆減少所緻齣血性疾病，其患者外週血小闆計數＜100×109/L，但沒有引起血小闆減少的明顯誘因或基礎疾病。近年來，隨著對此疾病髮病機製的認識逐漸深入，在其治療方麵也有瞭很多新的進展。
원발성면역성혈소판감소증시일충면역개도적획득성혈소판감소소치출혈성질병，기환자외주혈소판계수＜100×109/L，단몰유인기혈소판감소적명현유인혹기출질병。근년래，수착대차질병발병궤제적인식축점심입，재기치료방면야유료흔다신적진전。
Primary immune thrombocytopenia (ITP) is an immune-mediated acquired bleeding disorder characterized by isolated thrombocytopenia due to increased platelet clearance and/or impaired thrombocytogenesis, to which the peripheral platelet count in patients is less than 100×109/L, however, there is no obvious inducing factor or underlying disease resulting in thrombocytopenia. Much new progress has been made in the treatment of primary ITP in recent years with the deeply understanding of its pathogenesis.
